Vantage logo

Treme climbs a new mountain

Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.

Vantage logo

Go or no go? A first for Nefecon

Calliditas is hoping for its first approval, while Abbvie is gearing up to enter the crowded migraine space with an oral anti-CGRP project.